---
document_datetime: 2025-10-06 09:51:53
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/capvaxive-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: capvaxive-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4361969
conversion_datetime: 2025-12-27 15:47:24.452831
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## CAPVAXIVE

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 06/10/2025                          |                                             | SmPC and PL                      | To extend the shelf-life of the Capvaxive finished |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000296295                     | finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                             |            |     |             | product in accordance with the approved stability protocol, from 30 to 36 months when stored in a refrigerator (2°C - 8°C).                                                                                                                                                                                                                                                                                                       |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000285849 | B.I.c.2 Change in the specification parameters and/or limits of the immediate packaging of the active substance - B.I.c.2.c Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Accepted                                                                 | 28/07/2025 | N/A |             |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Variation type IB / EMA/VR/0000281543 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Change in supplier of sterilised primary container components, which are to be used in the aseptic manufacture of medicinal products - Accepted            | 18/07/2025 | N/A |             |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Variation type II / EMA/VR/0000267723 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.8 and 5.1 of the SmPC in order to update immunogenicity and | 10/07/2025 |     | SmPC and PL | SmPC new text - Section 4.8 Safety in adults with increased risk for pneumococcal disease An additional study, Protocol 008, was conducted to evaluate CAPVAXIVE in pneumococcal vaccine naïve adults 18 to 64 years of age with one or more prespecified chronic medical conditions known to increase the risk of pneumococcal disease. The safety profile of CAPVAXIVE was generally comparable to PCV15 followed by PPSV23 and |

<div style=\"page-break-after: always\"></div>

|                                       | safety information based on the final results from study V116-008 (EUCT: 2022-502791- 22-01); this is a phase 3, randomized, double-blind, active comparator-controlled clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve adults 18 to 64 years of age with increased risk for pneumococcal disease. In addition, the MAH took the opportunity to introduce editorial changes to the PI and to update the list of local representatives in the Package Leaflet.   |            | generally similar to the profile observed in the pivotal studies. - Section 5.1 Adults with increased risk for pneumococcal disease Protocol 008 In a double-blind study, 518 individuals 18 to 64 years of age with one or more prespecified chronic medical conditions known to increase the risk of pneumococcal disease (diabetes mellitus, chronic heart disease, chronic kidney disease, chronic liver disease, or chronic lung disease) were randomised in a 3:1 ratio to receive either CAPVAXIVE followed by placebo 8 weeks later, or PCV15 followed by PPSV23 (PCV15+PPSV23) 8 weeks later. The study participants had not previously received any pneumococcal vaccines other than routine childhood PCVs. CAPVAXIVE was immunogenic for all 21 serotypes contained in the vaccine, as assessed by serotype specific OPA GMTs at 1 month postvaccination with CAPVAXIVE. CAPVAXIVE elicited immune responses that were generally comparable to PCV15+PPSV23 for the 13 common serotypes and higher for the 8 serotypes unique to CAPVAXIVE as assessed by OPA GMTs at 1 month postvaccination with CAPVAXIVE and 1 month postvaccination with PCV15+PPSV23. For more information, please refer to the Summary of Product   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000267597 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                       | 10/06/2025 | SmPC and PL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000264668   | This was an application for a group of variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.a Tightening of in- process limits - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.a Tightening of in- process limits - Accepted   | 28/04/2025   | N/A   |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|